Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
LMNX's Cash to Debt is ranked higher than
98% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. LMNX: No Debt )
LMNX' s 10-Year Cash to Debt Range
Min: 11.48   Max: No Debt
Current: No Debt

Equity to Asset 0.90
LMNX's Equity to Asset is ranked higher than
96% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. LMNX: 0.90 )
LMNX' s 10-Year Equity to Asset Range
Min: 0.77   Max: 0.96
Current: 0.9

0.77
0.96
Interest Coverage 4689.50
LMNX's Interest Coverage is ranked higher than
78% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.94 vs. LMNX: 4689.50 )
LMNX' s 10-Year Interest Coverage Range
Min: 5.66   Max: 9999.99
Current: 4689.5

5.66
9999.99
F-Score: 9
Z-Score: 12.08
M-Score: -2.63
WACC vs ROIC
5.94%
19.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 12.40
LMNX's Operating margin (%) is ranked higher than
82% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.17 vs. LMNX: 12.40 )
LMNX' s 10-Year Operating margin (%) Range
Min: -1523.06   Max: 12.93
Current: 12.4

-1523.06
12.93
Net-margin (%) 17.20
LMNX's Net-margin (%) is ranked higher than
94% of the 312 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. LMNX: 17.20 )
LMNX' s 10-Year Net-margin (%) Range
Min: -1449.74   Max: 17.2
Current: 17.2

-1449.74
17.2
ROE (%) 13.50
LMNX's ROE (%) is ranked higher than
86% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. LMNX: 13.50 )
LMNX' s 10-Year ROE (%) Range
Min: -90.69   Max: 13.24
Current: 13.5

-90.69
13.24
ROA (%) 12.05
LMNX's ROA (%) is ranked higher than
92% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.84 vs. LMNX: 12.05 )
LMNX' s 10-Year ROA (%) Range
Min: -82.92   Max: 11.77
Current: 12.05

-82.92
11.77
ROC (Joel Greenblatt) (%) 34.06
LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.69 vs. LMNX: 34.06 )
LMNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -678.57   Max: 39.99
Current: 34.06

-678.57
39.99
Revenue Growth (3Y)(%) 7.50
LMNX's Revenue Growth (3Y)(%) is ranked higher than
81% of the 265 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. LMNX: 7.50 )
LMNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.5   Max: 191.1
Current: 7.5

7.5
191.1
EBITDA Growth (3Y)(%) 5.60
LMNX's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. LMNX: 5.60 )
LMNX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -69.3   Max: 45.3
Current: 5.6

-69.3
45.3
EPS Growth (3Y)(%) 39.90
LMNX's EPS Growth (3Y)(%) is ranked higher than
93% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.20 vs. LMNX: 39.90 )
LMNX' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.7   Max: 104.9
Current: 39.9

-52.7
104.9
» LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LMNX Guru Trades in Q1 2014

Jim Simons 111,497 sh (+4.07%)
PRIMECAP Management 2,386,259 sh (-3.59%)
» More
Q2 2014

LMNX Guru Trades in Q2 2014

Paul Tudor Jones 25,725 sh (New)
Jim Simons 128,140 sh (+14.93%)
PRIMECAP Management 2,040,232 sh (-14.50%)
» More
Q3 2014

LMNX Guru Trades in Q3 2014

Joel Greenblatt 38,571 sh (New)
PRIMECAP Management 1,987,848 sh (-2.57%)
Paul Tudor Jones 16,667 sh (-35.21%)
Jim Simons 17,200 sh (-86.58%)
» More
Q4 2014

LMNX Guru Trades in Q4 2014

Jim Simons 109,200 sh (+534.88%)
Joel Greenblatt 96,646 sh (+150.57%)
Paul Tudor Jones 22,867 sh (+37.20%)
PRIMECAP Management 1,904,718 sh (-4.18%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.00
LMNX's P/E(ttm) is ranked higher than
93% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 57.30 vs. LMNX: 17.00 )
LMNX' s 10-Year P/E(ttm) Range
Min: 16.79   Max: 646.43
Current: 17

16.79
646.43
Forward P/E 25.97
LMNX's Forward P/E is ranked higher than
71% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 60.61 vs. LMNX: 25.97 )
N/A
PE(NRI) 17.20
LMNX's PE(NRI) is ranked higher than
94% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 58.80 vs. LMNX: 17.20 )
LMNX' s 10-Year PE(NRI) Range
Min: 16.79   Max: 603.33
Current: 17.2

16.79
603.33
P/B 2.10
LMNX's P/B is ranked higher than
79% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. LMNX: 2.10 )
LMNX' s 10-Year P/B Range
Min: 2.07   Max: 12.27
Current: 2.1

2.07
12.27
P/S 2.90
LMNX's P/S is ranked higher than
55% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.21 vs. LMNX: 2.90 )
LMNX' s 10-Year P/S Range
Min: 2.87   Max: 12.99
Current: 2.9

2.87
12.99
PFCF 20.40
LMNX's PFCF is ranked higher than
91% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 91.20 vs. LMNX: 20.40 )
LMNX' s 10-Year PFCF Range
Min: 20.06   Max: 451.73
Current: 20.4

20.06
451.73
POCF 13.66
LMNX's POCF is ranked higher than
89% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.48 vs. LMNX: 13.66 )
LMNX' s 10-Year POCF Range
Min: 13.32   Max: 301.5
Current: 13.66

13.32
301.5
EV-to-EBIT 20.89
LMNX's EV-to-EBIT is ranked higher than
85% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 36.88 vs. LMNX: 20.89 )
LMNX' s 10-Year EV-to-EBIT Range
Min: -858.9   Max: 232.4
Current: 20.89

-858.9
232.4
PEG 0.77
LMNX's PEG is ranked higher than
98% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 0.77 )
LMNX' s 10-Year PEG Range
Min: 1.27   Max: 5.38
Current: 0.77

1.27
5.38
Shiller P/E 40.90
LMNX's Shiller P/E is ranked higher than
82% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 40.90 )
LMNX' s 10-Year Shiller P/E Range
Min: 39.62   Max: 386.75
Current: 40.9

39.62
386.75
Current Ratio 5.83
LMNX's Current Ratio is ranked higher than
92% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. LMNX: 5.83 )
LMNX' s 10-Year Current Ratio Range
Min: 4.25   Max: 19.82
Current: 5.83

4.25
19.82
Quick Ratio 4.62
LMNX's Quick Ratio is ranked higher than
92% of the 313 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. LMNX: 4.62 )
LMNX' s 10-Year Quick Ratio Range
Min: 3.56   Max: 19.23
Current: 4.62

3.56
19.23
Days Inventory 176.43
LMNX's Days Inventory is ranked higher than
64% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 137.40 vs. LMNX: 176.43 )
LMNX' s 10-Year Days Inventory Range
Min: 69.92   Max: 274.18
Current: 176.43

69.92
274.18
Days Sales Outstanding 46.79
LMNX's Days Sales Outstanding is ranked higher than
90% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 70.03 vs. LMNX: 46.79 )
LMNX' s 10-Year Days Sales Outstanding Range
Min: 38.52   Max: 153.06
Current: 46.79

38.52
153.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.10
LMNX's Price/Net Cash is ranked higher than
91% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 12.10 )
LMNX' s 10-Year Price/Net Cash Range
Min: 3.74   Max: 41.64
Current: 12.1

3.74
41.64
Price/Net Current Asset Value 7.00
LMNX's Price/Net Current Asset Value is ranked higher than
91% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 7.00 )
LMNX' s 10-Year Price/Net Current Asset Value Range
Min: 2.85   Max: 17.85
Current: 7

2.85
17.85
Price/Tangible Book 3.10
LMNX's Price/Tangible Book is ranked higher than
80% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.90 vs. LMNX: 3.10 )
LMNX' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 16.94
Current: 3.1

2.65
16.94
Price/DCF (Projected) 1.50
LMNX's Price/DCF (Projected) is ranked higher than
88% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.24 vs. LMNX: 1.50 )
LMNX' s 10-Year Price/DCF (Projected) Range
Min: 1.76   Max: 11.52
Current: 1.5

1.76
11.52
Price/Median PS Value 0.50
LMNX's Price/Median PS Value is ranked higher than
96% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. LMNX: 0.50 )
LMNX' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 12.24
Current: 0.5

0.6
12.24
Price/Peter Lynch Fair Value 1.30
LMNX's Price/Peter Lynch Fair Value is ranked higher than
97% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 1.30 )
LMNX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.43   Max: 13.1
Current: 1.3

1.43
13.1
Price/Graham Number 1.50
LMNX's Price/Graham Number is ranked higher than
93% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMNX: 1.50 )
LMNX' s 10-Year Price/Graham Number Range
Min: 1.81   Max: 9.41
Current: 1.5

1.81
9.41
Earnings Yield (Greenblatt) 4.80
LMNX's Earnings Yield (Greenblatt) is ranked higher than
81% of the 306 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. LMNX: 4.80 )
LMNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 5
Current: 4.8

0.4
5
Forward Rate of Return (Yacktman) 16.01
LMNX's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. LMNX: 16.01 )
LMNX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -53.6   Max: 32.4
Current: 16.01

-53.6
32.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:LMX.Germany,
Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 
Luminex Corporation Reports Second Quarter 2009 Results Aug 06 2009 
Luminex Corporation Reports Fourth Quarter and Year-End 2008 Results Feb 05 2009 
Luminex Corporation Fourth Quarter and Year End 2008 Earnings Release Scheduled for February 5, 2009 Jan 21 2009 

More From Other Websites
Luminex Corporation Reports First Quarter 2015 Results May 04 2015
Luminex tops Street 1Q forecasts May 04 2015
Luminex tops Street 1Q forecasts May 04 2015
Luminex Corp Earnings Call scheduled for 4:30 pm ET today May 04 2015
4:14 pm Luminex beats by $0.10, beats on revs; guides Q2 & FY15 revs in-line May 04 2015
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 04 2015
Luminex Corporation Reports First Quarter 2015 Results May 04 2015
Q1 2015 Luminex Corp Earnings Release - After Market Close May 04 2015
Luminex Rallies on Positive ARIES Clinical Trial Update - Analyst Blog Apr 29 2015
Luminex Corporation Provides Updates on ARIES® Clinical Trials Apr 27 2015
Luminex Corporation Provides Updates on ARIES® Clinical Trials Apr 27 2015
Thermo Fisher Q1 Earnings Top, Revenues Lag Estimates - Analyst Blog Apr 22 2015
Inogen Gains despite Further Delay in Form 10-K Filing - Analyst Blog Apr 16 2015
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog Apr 15 2015
Intuitve Surgical's Product Line Strong, Hits 52-Week High - Analyst Blog Apr 14 2015
Luminex Corporation First Quarter Earnings Release Scheduled for May 4, 2015 Apr 13 2015
Luminex Corporation First Quarter Earnings Release Scheduled for May 4, 2015 Apr 13 2015
DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog Apr 10 2015
Luminex (LMNX) Launches NxTAG RPP for Respiratory Testing - Analyst Blog Apr 07 2015
A New Test to Simultaneously Detect 22 Respiratory Pathogens Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK